Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017147894) COMPOSITION FOR ENHANCING CAPACITY TO KILL ABNORMAL CELLS AND USE THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2017/147894 International Application No.: PCT/CN2016/075595
Publication Date: 08.09.2017 International Filing Date: 04.03.2016
IPC:
C12N 5/0783 (2010.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07
Animal cells or tissues
071
Vertebrate cells or tissues, e.g. human cells or tissues
078
Cells from blood or from the immune system
0783
T cells; NK cells; Progenitors of T or NK cells
Applicants:
张明杰 ZHANG, Mingjie [US/CN]; CN
Inventors:
张明杰 ZHANG, Mingjie; CN
Agent:
北京清亦华知识产权代理事务所(普通合伙) TSINGYIHUA INTELLECTUAL PROPERTY LLC; 中国北京市 海淀区清华园清华大学照澜院商业楼301室 Room 301 Trade Building, Zhaolanyuan, Tsinghua University, Qinghuayuan, Haidian District Beijing 100084, CN
Priority Data:
Title (EN) COMPOSITION FOR ENHANCING CAPACITY TO KILL ABNORMAL CELLS AND USE THEREOF
(FR) COMPOSITION AMÉLIORANT LA CAPACITÉ À TUER DES CELLULES ANORMALES, ET UTILISATION ASSOCIÉE
(ZH) 增强对异常细胞杀伤力的组合物及其应用
Abstract:
(EN) Disclosed are a composition for enhancing capacity to kill abnormal cells and a pharmaceutical use thereof. The composition consists of a natural killer (NK) cell and a T lymphocyte selected from one of the following: a tumor-infiltrating lymphocyte (TIL) and a cytotoxic T cell (CTL). The NK cell comprises a high-affinity NK (HANK) cell obtained by using an empty cell envelope carrying a cytokine to perform in vitro activation of an in vivo NK cell. The NK cell comprising the HANK cell is administered to a patient in combination with the TIL and/or CTL. The HANK cell and the TIL or the CTL can mutually enhance the capacity thereof to kill abnormal cells.
(FR) L'invention concerne une composition permettant d'améliorer la capacité à tuer des cellules anormales, et une utilisation pharmaceutique associée. La composition est constituée d'une cellule tueuse naturelle (NK) et d'un lymphocyte T choisi parmi l'un des éléments suivants : un lymphocyte infiltrant les tumeurs (TIL) et un lymphocyte T cytotoxique (CTL). La cellule NK comprend une cellule NK à haute affinité (HANK) obtenue en utilisant une enveloppe cellulaire vide transportant une cytokine pour procéder à l'activation in vitro d'une cellule NK in vivo. La cellule NK comprenant la cellule HANK est administrée à un patient en association avec le TIL et/ou le CTL. La cellule HANK et le TIL ou le CTL peuvent mutuellement améliorer leur capacité à tuer des cellules anormales.
(ZH) 一种增强对异常细胞杀伤力的组合物和制药用途,所述组合物由自然杀伤细胞和以下一种T淋巴细胞组成:肿瘤浸润性淋巴细胞和细胞毒性T细胞,自然杀伤细胞包含高活性自然杀伤细胞,高活性自然杀伤细胞通过利用带有细胞因子的细胞空壳体外活化体内自然杀伤细胞而获得。将包含HANK细胞的NK细胞与TIL和/或CTL联合给予患者,HANK细胞和TIL或CTL之间能够互相增强对异常细胞的杀伤力。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)